ThermoFisherScientific - Custom and Bulks
Pharma Focus Europe
Worldwide Clinical Trials - Neuroscience Clinical Development

Ipsen and Marengo Therapeutics Announce Second Strategic Partnership to Advance Precision T-Cell Engager Assets in Marengo's TriSTAR Platform

Friday, June 07, 2024

Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics Inc, a clinical-stage biotechnology company, today announced the expansion of their current oncology research partnership to include Marengo’s innovative “T-Cell Engager” (TCE) technology, TriSTAR. Conventional TCEs targeting “cold” tumors have limited effectiveness due to poor quality and functional exhaustion of T cells. Forming a new therapeutic class, Marengo's TrisTAR TCEs have the potential to push these boundaries, by redirecting a new, expanded group of highly active memory Vβ T cells toward the tumor. The teams will primarily explore their potential in “cold” tumors, against which the body generally fails to produce a strong immune response when treated with traditional TCEs.

“We favor a scientific approach to the growth of our R&D product portfolio. As such, we look forward to continuing the considerable work already accomplished with the Marengo teams, who share our passion and our desire to accelerate innovation to better fight cancer,” declared David Jenkins, Senior Vice President, External Research & Innovation. “Marengo’s innovative TriSTAR platform offers us the ability to leverage the immune system, activating an expanded pool of T cells to eradicate tumors that typically respond poorly to T cell immunotherapies.”

“We are excited to expand our research partnership with Ipsen, which already brought a first candidate into the clinic earlier this year,” said Zhen Su, CEO of Marengo Therapeutics. “This new collaboration with Ipsen builds on both our clinically validated T cell activation platform via the Vβ T cell receptor (TCR), and our internal work targeting new “T-Cell Engagers” active ingredients. of the TriSTAR platform. These present the best potential in their class to achieve the ultimate goal of precision immunotherapies: that of directing the right T cells to the right tumor. The TriSTAR platform significantly enriches our portfolio to target difficult-to-treat “cold” tumors, and we are pleased to partner with the Ipsen oncology team to achieve this ambition together. »

Under the terms of the agreement, Ipsen will assume responsibility for all activities once the clinical development candidate is selected. Marengo will receive an upfront payment, as well as potential additional payments of up to $1.2 billion in total if all development and commercialization milestones are reached, in addition to tiered royalty payments on overall sales. .

About Ipsen

We are a global biopharmaceutical group focused on developing innovative medicines for patients in three therapeutic areas: Oncology, Rare Diseases and Neurosciences.

Our R&D product portfolio draws on external innovation and nearly 100 years of development experience in global hubs in the US, France and the UK. Our teams, present in more than 40 countries, and our partnerships around the world allow us to offer our medicines to patients in more than 80 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the United States through a sponsored Level I American Depositary Receipt (ADR: IPSEY) program. For more information, visit ipsen.com

About Marengo

Marengo Therapeutics, Inc, a clinical-stage biotechnology company, is developing novel TCR-targeting antibodies that selectively modulate common T cell subsets of the TCR repertoire in germline configuration to promote lifelong protection against cancer and other diseases. Backed by a team of passionate, committed and experienced researchers in immuno-oncology, Marengo's exclusive STAR (Selective T Cell Activation Repertoire) platform is based on an in-depth biological understanding of T cell function and receptor signaling. to shape a world where everyone can beat cancer with their own immune system. To find out more, go to: marengotx.com.

About the TriSTAR platform

Marengo's TriSTAR platform is a multispecific antibody-fusion platform derived from Marengo's proprietary library of antibodies targeting the germline-encoded variable Vβ regions of the TCR, fused to a T-cell co-stimulatory moiety and a binder. of tumor-associated antigen. By expanding and redirecting a new pool of highly active memory Vβ T cells, TriSTAR TCEs have the potential to overcome the effects of poor T cell quality and functional exhaustion, which typically limit the activity of traditional TCEs .

Email: corporate.communications@ipsen.com

Ipsen Contacts

Investors

Craig Marks | +44 7584 349 193

Nicolas Bogler | +33 (0) 6 52 19 98 92

Media

Amy Wolf | +41 7 95 76 07 23

Jess Smith | +44 7557 267 634

Marengo Contacts

Investors

Svetlana Makhni | smakhni@marengotx.com

Media

Peg Rusconi | peg.rusconi@vergescientific.com

Cautions and/or Forward-Looking Statements

The forward-looking statements and objectives contained in this release are based on the current strategy and assumptions of Ipsen's management. These statements and objectives depend on known or unknown risks and uncertainties which may cause the actual results, performance or events to differ materially from those contemplated in this press release. Such risks and unforeseen circumstances could affect Ipsen's ability to achieve its objectives. financial statements, which are based on reasonable assumptions about future macroeconomic conditions based on information available to date. The use of the terms "believes", "intends" and "plans" or similar expressions is intended to identify forward-looking statements, including Ipsen's expectations regarding future events such as regulatory submissions and decisions. Furthermore, the objectives mentioned in this document are established without taking into account possible future external growth operations which could modify all of these parameters. These forecasts are based in particular on data and assumptions considered reasonable by Ipsen, and depend on circumstances or facts likely to occur in the future, some of which are beyond the Group's control, and not exclusively on historical data. The actual results could prove to be substantially different from these objectives given the materialization of certain risks or uncertainties, and in particular that a new drug may appear promising during a preparatory phase of development or after clinical trials, but not never be commercialized or fail to achieve its commercial objectives, particularly for regulatory or competitive reasons. Ipsen must or may have to face competition from generic products, which could result in losses of market share. Furthermore, the research and development process includes several stages and, at each stage, there is a significant risk that Ipsen will not be able to achieve its objectives and that it will be forced to abandon its efforts on a drug in which he invested significant sums. Also, Ipsen cannot be certain that favorable results obtained during preclinical trials will be subsequently confirmed during clinical trials or that the results of clinical trials will be sufficient to demonstrate the safety and effectiveness of the medicine in question. There can be no assurance that any drug will receive necessary regulatory approvals or achieve its commercial objectives. Actual results could differ materially from those anticipated in the forward-looking statements if underlying assumptions prove inaccurate or if certain risks or uncertainties materialize. Other risks and uncertainties include,but not limited to, the general situation of the sector and competition; general economic factors, including fluctuations in interest rates and foreign exchange rates; the impact of pharmaceutical industry regulation and healthcare legislation; global trends towards greater control of healthcare costs; technological advances, new drugs and patents obtained by competitors; problems inherent in the development of new drugs, including obtaining approval; Ipsen's ability to accurately forecast future market conditions; production difficulties or delays; financial instability of the international economy and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the risk of litigation, including patent litigation or regulatory challenges. Ipsen also depends on third parties for the development and marketing of its medicines, which may result in substantial royalties; furthermore, these partners could act in such a way as to harm Ipsen's activities as well as its financial results. Ipsen cannot be certain that its partners will keep their commitments. As such, the Group may not be able to benefit from these agreements. A failure of one of its partners could lead to an unforeseen drop in revenue for Ipsen. Such situations could have a negative impact on Ipsen's business, its financial situation or its results. Subject to applicable legal provisions, Ipsen undertakes no obligation to update or revise the forward-looking or objective statements referred to in this press release in order to reflect changes which would affect the events, situations, assumptions or circumstances on which these statements melt together. Ipsen's activity is subject to risk factors which are described in its information documents registered with the Autorité des Marchés Financiers. The risks and uncertainties presented are not the only ones that the Group must face and the reader is invited to read the latest edition of Ipsen's Universal Registration Document, available onin particular obtaining approval; Ipsen's ability to accurately forecast future market conditions; production difficulties or delays; financial instability of the international economy and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the risk of litigation, including patent litigation or regulatory challenges. Ipsen also depends on third parties for the development and marketing of its medicines, which may result in substantial royalties; furthermore, these partners could act in such a way as to harm Ipsen's activities as well as its financial results. Ipsen cannot be certain that its partners will keep their commitments. As such, the Group may not be able to benefit from these agreements. A failure of one of its partners could lead to an unforeseen drop in revenue for Ipsen. Such situations could have a negative impact on Ipsen's business, its financial situation or its results. Subject to applicable legal provisions, Ipsen undertakes no obligation to update or revise the forward-looking or objective statements referred to in this press release in order to reflect changes which would affect the events, situations, assumptions or circumstances on which these statements melt together. Ipsen's activity is subject to risk factors which are described in its information documents registered with the Autorité des Marchés Financiers. The risks and uncertainties presented are not the only ones that the Group must face and the reader is invited to read the latest edition of Ipsen's Universal Registration Document, available onin particular obtaining approval; Ipsen's ability to accurately forecast future market conditions; production difficulties or delays; financial instability of the international economy and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the risk of litigation, including patent litigation or regulatory challenges. Ipsen also depends on third parties for the development and marketing of its medicines, which may result in substantial royalties; furthermore, these partners could act in such a way as to harm Ipsen's activities as well as its financial results. Ipsen cannot be certain that its partners will keep their commitments. As such, the Group may not be able to benefit from these agreements. A failure of one of its partners could lead to an unforeseen drop in revenue for Ipsen. Such situations could have a negative impact on Ipsen's business, its financial situation or its results. Subject to applicable legal provisions, Ipsen undertakes no obligation to update or revise the forward-looking or objective statements referred to in this press release in order to reflect changes which would affect the events, situations, assumptions or circumstances on which these statements melt together. Ipsen's activity is subject to risk factors which are described in its information documents registered with the Autorité des Marchés Financiers. The risks and uncertainties presented are not the only ones that the Group must face and the reader is invited to read the latest edition of Ipsen's Universal Registration Document, available onits financial situation or its results. Subject to applicable legal provisions, Ipsen undertakes no obligation to update or revise the forward-looking or objective statements referred to in this press release in order to reflect changes which would affect the events, situations, assumptions or circumstances on which these statements melt together. Ipsen's activity is subject to risk factors which are described in its information documents registered with the Autorité des Marchés Financiers. The risks and uncertainties presented are not the only ones that the Group must face and the reader is invited to read the latest edition of Ipsen's Universal Registration Document, available onits financial situation or its results. Subject to applicable legal provisions, Ipsen undertakes no obligation to update or revise the forward-looking or objective statements referred to in this press release in order to reflect changes which would affect the events, situations, assumptions or circumstances on which these statements melt together. Ipsen's activity is subject to risk factors which are described in its information documents registered with the Autorité des Marchés Financiers. The risks and uncertainties presented are not the only ones that the Group must face and the reader is invited to read the latest edition of Ipsen's Universal Registration Document, available onipsen.com .

 

Source: globenewswire.com

magazine-slider-img
Thermo Fisher Scientific viral vector services (VVS)ThermoFisher - Mastering API production at every scaleFuture Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva